Document Detail


Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
MedLine Citation:
PMID:  25307456     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggregation inhibitors and/or cytoreductive agents depending on the underlying disease and the individual risk. Clinical evidence for management of acute venous thromboembolic events in MPN patients is limited. Modality and duration of therapeutic anticoagulation after venous thrombosis has to be evaluated critically with special regard to the increased risk for spontaneous bleeding events associated with the underlying diseases. Both for therapy of the acute event and for secondary prophylaxis, low-molecular-weight heparins should preferentially be used. A prolongation of the therapeutic anticoagulation beyond the usual 3 to 6 months can only be recommended in high-risk settings and after careful evaluation of potential risks and benefits for the individual patient. New direct oral anticoagulants (NOAC) should not preferentially be used due to lack of clinical experience in patients with MPN and potential drug interactions (e.g. with JAK inhibitors). Consequent treatment of the underlying myeloproliferative disease and periodical evaluation of the response to therapy is crucial for optimal secondary prophylaxis of thromboembolic events in those patients.
Authors:
Stephan Kreher; Sebastian Ochsenreither; Ralf U Trappe; Ingrid Pabinger; Frauke Bergmann; Petro E Petrides; Steffen Koschmieder; Axel Matzdorff; Andreas Tiede; Martin Griesshammer; Hanno Riess
Related Documents :
22592186 - Higher mortality among remote compared to rural or urban dwelling hemodialysis patients...
22710946 - Intermittent self-catheterization habits and opinion on aseptic vapro catheter in frenc...
8504046 - Recurrent erythema multiforme: clinical features and treatment in a large series of pat...
2389766 - Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmaphe...
25057036 - Mortality and causes of death among incident cases of systemic lupus erythematosus in f...
20367136 - Characteristics and outcomes after autologous stem cell transplant for patients with re...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-10-14
Journal Detail:
Title:  Annals of hematology     Volume:  -     ISSN:  1432-0584     ISO Abbreviation:  Ann. Hematol.     Publication Date:  2014 Oct 
Date Detail:
Created Date:  2014-10-13     Completed Date:  -     Revised Date:  2014-10-14    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Advances in Neurocritical Care.
Next Document:  Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell trans...